- Brand name:
- Pharmaceutical Company:
- Condition/Indication: Behavioural and psychological symptoms of dementia (BPSD)
- Meeting Date: August 2019
- Public Summary Document (PSD) August 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) August 2019 PBAC Meeting - (Word 181KB)
Risperidone – August 2019
RISPERIDONE: 500 microgram and 1 mg tablet, 1mg/mL oral liquid, Various Sponsors
Last updated
9 July 2025